More than half of myasthenia gravis (MG) patients have fatigue, the severity of which is strongly correlated with their history of exacerbations, that is episodes when their disease worsens, and/or crises, along with delays in their diagnosis. That’s according to a nationwide registry study in Germany that found…
News
The volume of the extraocular muscles controlling eye movements is decreased in Chinese patients with myasthenia gravis (MG), particularly in those with ophthalmoparesis, or limited eye movement, a study found. Long disease duration was also associated with decreased extraocular muscle volume, but only in patients with ophthalmoparesis. A reduction…
Rituximab effectively treated most myasthenia gravis (MG) patients who were positive for antibodies against muscle-specific tyrosine kinase (MuSK), a small study shows. The therapy eased MG symptoms and led to gains in measures of clinical severity. It also enabled patients to reduce or stop taking other medications,…
More than a quarter of patients with generalized myasthenia gravis (gMG) spend more than a year waiting for an accurate diagnosis, according to a survey-based study conducted across five European countries. Study findings also suggested that patients who waited more than one year to be diagnosed might have…
Treatment with Soliris (eculizumab) was effective for managing myasthenic crisis in four people with myasthenia gravis (MG) at a center in China, a study reported. “[Soliris] exhibited a tolerable and efficacious profile in treating patients with [myasthenic crisis],” the researchers wrote, adding that “larger sample sizes and longer…
Kyverna Therapeutics’ experimental cell therapy, KYV-101, has been granted regenerative medicine advanced therapy (RMAT) status by the U.S. Food and Drug Administration (FDA) for treating progressive myasthenia gravis (MG). RMAT designation is intended to expedite the development and FDA review of experimental regenerative treatments that treat, modify, reverse,…
By March, Immunovant plans to initiate four or five pivotal clinical trials of its lead therapeutic candidate IMVT-1402 across a range of autoimmune conditions, including myasthenia gravis (MG). Pivotal, or registrational, trials are large-scale studies whose data could support regulatory applications seeking a therapy’s approval. Immunovant announced…
Patients with generalized myasthenia gravis (gMG) with mild pre-surgery muscle weakness had more favorable outcomes after a thymectomy, which involves the surgical removal of the thymus gland, than those with moderate or severe muscle weakness, a study finds. In their study, “Pre-thymectomy disease severity predicts outcome in…
Remegen enrolled the first U.S. patient in a Phase 3 trial testing the safety and efficacy of telitacicept to treat generalized myasthenia gravis (gMG), according to a company press release, This Phase 3 clinical trial (NCT06456580) is a global, multi-center, randomized, double-blind, placebo-controlled study in which…
The anti-malaria drug dihydroartemisinin, known simply as DHA, showed promise in a rat model of myasthenia gravis (MG) as a potential treatment for the autoimmune disease, a new study reports. In addition to alleviating many MG-related symptoms, DHA inhibited pro-inflammatory T-cells while boosting immune-suppressing T-regulatory cells. Treatment with the…
Recent Posts
- Women with MG have higher risk of complications during pregnancy
- This year, I’m pushing boundaries in how I live with MG
- Early rituximab treatment may improve long-term outcomes in gMG
- Vyvgart plus low-dose steroids is safer treatment for severe gMG: Study
- Guest Voice: Don’t let fear hold you back from living fully with MG